MECFA Blog

News & Articles

Commission approves medical marijuana facilities

Stratford could eventually have two medical marijuana dispensaries in town, based on a Zoning Commission vote at the Nov. 14 meeting allowing the facilities. “It’s time,” said Commissioner Dave Fuller, who made the motion to approve the required change in the zoning regulations. The commission voted unanimously to approve the so-called text amendment change, which means the wording of the regulations is being altered to allow medical marijuana dispensaries. The new policy specifically sets a limit of two dispensaries in Stratford and includes numerous other restrictions. For instance, dispensaries won’t be allowed in residential zoning districts. The regulation change allows only facilities

Case Report Provides New Insights on Dosing of Novel Drug for Patients with Cystic Fibrosis

Ceftolozane/tazobactam is safe, effective, and well-tolerated in the treatment of multidrug-resistant Pseudomonas aeruginosa infection (MDR-PSA)—even in a post-lung transplant patient with pulmonary exacerbation complicated by comorbid cystic fibrosis, malnutrition, and chronic kidney disease. At least this was the conclusion of a case report published online recently in the journal Respiratory Medicine Case Reports. The report, which also offers insights into the pharmacokinetics-pharmacodynamics of the novel second-generation β-lactam/β-lactamase inhibitor while also recommending a framework for dosing, will be published in the print edition of the journal in 2018. According to data pr

Europe’s CHMP Gives Its Blessing to Vertex’s Orkambi as CF Therapy for Younger Children

The European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Orkambi (ivacaftor/lumacaftor) as a therapy for cystic fibrosis (CF) in children. The ruling is specifically for pediatric patients aged 6 to 11 with two copies of the F508del mutation in the CFTR gene. CF, an inherited disease, affects about 12,000 people aged 12 years and older in Europe, and more than 30,000 people in the United States. It is caused by a defective or absent CFTR protein, the result of mutations in the CFTR gene. Having two copies of the F508del mutation in the CFTR gene — one from each parent — is the leading cause of CF. This mutation results in little to n

Help Comes in the Form of Biosensors for Cystic Fibrosis Patients

A new biosensor tool’s been developed by Imperial researchers that lights up when any harmful bacteria is detected in the lung. Biosensors have been around a while now and are designed using engineered DNA circuits and work by detecting changes to their host’s environment such as changes in temperature or pH, or upon the detection of certain chemicals. They are perfect for being used to detect chemical traces of harmful bacteria in the lung quickly. Moving forward the researchers are hopeful they’ll be able to create cell-free sensors in the future and integrate them into diagnostic tests to be used in clinics, surgeries, or even at home. This would be a fantastic benefit for those in remo

Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Li

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and their immediate family members. In its second year, the All in for CF Scholarship program will award 80 scholarships of $5,000 each to help people with cystic fibrosis (CF) and their immediate family members pursue two-year, four-year or graduate degrees during the 2018-2019 academic year. This scholarship program is part of Vertex’s recently announced 10-year, $500 million corporate giving commitment. “At Vertex, our passion is fueled by the hope and courage of the CF community, which is clearly reflected in each All in for CF scholar,” said Jeffrey Leide

Mucociliary Clearence

Scott Donaldson, M.D., an associate professor of medicine and the director of the University of North Carolina adult CF center, provides an update on new developments in mucociliary clearance. These clinical trials are designed to thin or alter the thick, sticky mucus in the lungs of people with cystic fibrosis so that it can be coughed out more easily.

#NACFC2017 – Latest Trial Data on Vertex CF Therapies and New Combos Show Benefits

Vertex Pharmaceuticals recently presented data from several clinical trials of cystic fibrosis treatments showing positive outcomes for CF patients. Data focused on the approved therapies Orkambi and Kalydeco, and investigative treatments like tezacaftor/ivacaftor and several triple regimens. These findings were presented at the North American Cystic Fibrosis Conference (NACFC) that ran Nov. 2-4 in Indianapolis. Orkambi (ivacaftor/lumacaftor) data were shown in a poster “Safety and Efficacy of Lumacaftor/Ivacaftor (LUM/IVA) in Patients aged ≥6 years with CF Homozygous for F508del-CFTR (Phase 3 Extension Study).” It involved an analysis of an ongoing 96-week extension study (NCT03125395) of O

Featured Posts
Recent Posts
Archive
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean